Scarica l'app Stockscreener
112.99
0.25%
0.28
Dopo l'orario di chiusura:
113.13
0.14
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$112.71
Aprire:
$112.63
Volume 24 ore:
4.42M
Relative Volume:
0.65
Capitalizzazione di mercato:
$140.20B
Reddito:
$28.80B
Utile/perdita netta:
$6.31B
Rapporto P/E:
22.51
EPS:
5.02
Flusso di cassa netto:
$9.37B
1 W Prestazione:
-0.82%
1M Prestazione:
-0.17%
6M Prestazione:
-2.59%
1 anno Prestazione:
+41.77%
Intervallo 1D:
$112.15
$113.40
Intervallo di 1 settimana:
$111.28
$113.85
Portata 52W:
$77.74
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
112.99 | 139.85B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
737.83 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.00 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.86 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.23 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.18 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest
Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest
Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox
Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest
Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener
Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha
Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com
Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest
Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - The Derrick
$43B Economic Impact: Gilead Sciences Launches Massive U.S. Manufacturing Expansion with AI-Enabled Hub - Stock Titan
Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser
Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
How hedge fund analytics apply to Gilead Sciences Inc. stockTake Profit & Growth Oriented Trade Recommendations - Newser
What earnings revisions data tells us about Gilead Sciences Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - Newser
Using RSI to spot recovery in Gilead Sciences Inc.2025 Retail Activity & High Return Stock Watch Alerts - Newser
Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture Amid Mixed Analyst Sentiment - AInvest
What to expect from Gilead Sciences Inc. in the next 30 daysQuarterly Profit Review & Low Risk Entry Point Guides - Newser
Gilead's $0.5B Volume Ranks 215th as Q2 Sales Climb and Yeztugo Approval Signals Long-Term Innovation - AInvest
Market Trends: Can Gilead Sciences Inc. grow without external funding2025 Winners & Losers & Consistent Income Trade Ideas - khodrobank.com
Gilead eyes price hikes for HIV meds in state AIDS programs - Seeking Alpha
What Do Analysts Think About Gilead Sciences (GILD)? - MSN
Gilead Sciences - Fierce Pharma
Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales - Seeking Alpha
Visual trend scoring systems applied to Gilead Sciences Inc.July 2025 Analyst Calls & Short-Term High Return Ideas - Newser
Gilead Sciences, Inc. (GILD) Wins FDA Approval for World’s First Twice-Yearly HIV Preventive Therapy - Yahoo Finance
Pharming Group appoints Kenneth Lynard as Chief Financial Officer - GlobeNewswire Inc.
Forecasting Gilead Sciences Inc. price range with options dataTake Profit & Real-Time Chart Breakout Alerts - Newser
Gilead Sciences Inc. Recovery Likely Here’s What Data Shows getLinesFromResByArray error: size == 0 - thegnnews.com
Gilead Sciences’ SWOT analysis: HIV giant faces challenges, oncology promise - Investing.com
Is Gilead Sciences Inc. currently under institutional pressureTrade Entry Summary & Target Return Focused Picks - خودرو بانک
Will Gilead Sciences Inc. bounce back from current supportRate Hike & Growth Oriented Trading Recommendations - Newser
Technical analysis overview for Gilead Sciences Inc. stockQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Detecting support and resistance levels for Gilead Sciences Inc.Earnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission - MSN
Investors Hope for Bounce in Gilead Sciences Inc. After Selloff2025 Dividend Review & Weekly Setup with High ROI Potential - beatles.ru
Price action breakdown for Gilead Sciences Inc.Earnings Overview Summary & Safe Entry Trade Signal Reports - Newser
Paving the Way for the Future Pipeline: Gilead Builds New State-of-the-Art Research Center - Gilead Sciences
Gilead Climbs 0.36% on Strong-Buy Upgrade and Institutional Buys Despite 174th-Ranked 0.52B Volume - AInvest
Historical volatility pattern of Gilead Sciences Inc. visualizedJuly 2025 Setups & High Yield Equity Trading Tips - Newser
Gilead Sciences' Insider Selling: Liquidity Management or Early Warning Signal? - AInvest
Statistical indicators supporting Gilead Sciences Inc.’s strength2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Applying Wyckoff theory to Gilead Sciences Inc. stock2025 Geopolitical Influence & Advanced Technical Analysis Signals - Newser
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - MSN
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):